arrow
S

Susanna V. Ulahannan

University of Oklahoma Health Sciences Center
H指数:25
被引数:3,322

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2–SP1–SAT1 axis

作者更正:癌症相关成纤维细胞衍生的醋酸盐通过ACSS2–SP1–SAT1轴改变多胺代谢促进胰腺癌发展

2026-08-040
OA
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study

使用高级机器学习方法预测阿替利珠单抗联合贝伐珠单抗治疗晚期肝细胞癌的结局:一项回顾性队列研究

2026-02-120
OAAI
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: results of the DT-real study

在临床实践中,durvalumab联合或单药使用tremelimumab治疗肝细胞癌的可重复安全性及有效性:DT-real研究结果

2025-11-200
OAAI
Outcomes of durvalumab with or without tremelimumab in routine clinical practice according to HIMALAYA Trial Eligibility: preliminary results of the international DT-real study
2025-02-010
PRE
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies

抗淋巴细胞活化基因3抗体Fianlimab与Cemiplimab在晚期恶性肿瘤患者中的首次人体剂量递增研究

2024-10-180
OAAI
Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications

I期首个人体研究初步结果,该研究评估了共价PI3Kα抑制剂TOS-358在表达PI3Kα突变或扩增的实体瘤患者中的疗效。

2024-09-010
PRE
Lenvatinib versus sorafenib as a second-line option in patients with unresectable hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab: An observational study

仑伐替尼与索拉非尼作为接受过阿替利珠单抗联合贝伐珠单抗治疗的不切除肝细胞癌患者的二线治疗选择:一项观察性研究

2024-09-010
PRE
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

肝功能失代偿是使用阿特珠单抗联合贝伐单抗治疗的肝细胞癌患者死亡率的主要驱动因素: 成功抗病毒治疗的影响

2024-07-195
PRE
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

肝细胞癌患者与其他晚期实体瘤患者免疫治疗相关肝损伤的特征和结局

2024-03-0111
OA
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

肝细胞癌免疫治疗疗效和安全性性别差异的meta分析和真实世界队列研究

2024-02-016
OAAI
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
2024-02-010
PRE
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Divarasib联合西妥昔单抗治疗KRAS G12C-positive结直肠癌: 1b期临床试验

2023-12-0531
OAAI
Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers
2023-12-010
PRE
A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI plus bevacizumab compared to FOLFIRI plus bevacizumab alone in second line metastatic colorectal cancer
2023-12-011
PRE